Disclaimer: Healthline has made every effort to make certain that all information is factually correct, comprehensive, and up-to-date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or other healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
In the 8-week, double-blind period of the comparative trial with bromocriptine (cabergoline n=223; bromocriptine n=236 in the intent-to treat analysis), prolactin was normalized in 77% of the patients treated with DOSTINEX at mg twice weekly compared with 59% of those treated with bromocriptine at mg twice daily. Restoration of menses occurred in 77% of the women treated with DOSTINEX, compared with 70% of those treated with bromocriptine. Among patients with galactorrhea , this symptom disappeared in 73% of those treated with DOSTINEX compared with 56% of those treated with bromocriptine.
Initially, 50 mg/day PO in the evening. The dosage should be increased in increments of 50 mg/day depending upon individual response and tolerability. Dose range for manic episodes with or without mixed features in younger adults: 400 mg/day to 800 mg/day PO as monotherapy or as an adjunct to lithium or divalproex. Maximum: 800 mg/day PO. Consider slower titration and a lower target dose for debilitated patients and those at risk for hypotension. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Efficacy as monotherapy maintenance treatment has not been formally evaluated; therefore the recommended maintenance dose range is 400 mg/day to 800 mg/day as an adjunct to lithium or divalproex. Generally, continue on the same dose on which stabilized during the acute phase of treatment. RE-INITIATION OF TREATMENT: If therapy is discontinued for less than 1 week and subsequently re-initiated, the same dose/schedule may be used without titration. If therapy has been discontinued for more than 1 week, follow the initial titration schedule.